Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on BI 10773 PK in Healthy Males
NCT02172209Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2008
- Primary completion
- Feb 2008
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity at 72 hours and Maximum measured concentration of the analyte in plasma at 72 hours. Started Jan 2008; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02172209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02172209.